View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 13, 2011

Chembio syphilis assay obtains CE mark

Chembio Diagnostics, which develops, manufactures, markets and licences point-of-care diagnostic tests, has received CE marking for its Dual Path Platform syphilis screen and confirm assay.

Chembio Diagnostics, which develops, manufactures, markets and licences point-of-care diagnostic tests, has received CE marking for its Dual Path Platform syphilis screen and confirm assay.

Using Chembio’s patented DPP technology, the assay permits the simultaneous yet separate detection of both markers at the point of care.

The approval confirms that the product has met all relevant EU consumer safety, health or environmental requirements, and can therefore be sold within the European Economic Area.

The company has recently begun clinical trials in the US in support of an application to the FDA for 510(k) clearance, which the company anticipates submitting in 2012.

Chembio also anticipates that the test will be eligible for a Clinical Laboratory Improvement Act waiver, which, if granted, would allow use of the test in public health testing clinics and physician offices for screening of pregnant women.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management